IsoPlexis (IsoPlexis) Net Margin % : -988.16% (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. IsoPlexis's Net Income for the three months ended in Dec. 2022 was $-33.21 Mil. IsoPlexis's Revenue for the three months ended in Dec. 2022 was $3.36 Mil. Therefore, IsoPlexis's net margin for the quarter that ended in Dec. 2022 was -988.16%.

The historical rank and industry rank for IsoPlexis's Net Margin % or its related term are showing as below:

ISO' s Net Margin % Range Over the Past 10 Years
Min: -632.41 Med: -348.31 Max: -181.56
Current: -632.41

ISO's Net Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -0.41 vs ISO: -632.41

IsoPlexis Net Margin % Historical Data

The historical data trend for IsoPlexis's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis Net Margin % Chart

IsoPlexis Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Net Margin %

-181.56

-223.97

-472.64

-632.40

IsoPlexis Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Net Margin %	Get a 7-Day Free Trial								-455.74	-584.91	-639.35	-411.57	-988.16

Competitive Comparison of IsoPlexis's Net Margin %

For the Medical Devices subindustry, IsoPlexis's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IsoPlexis's Net Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's Net Margin % distribution charts can be found below:

* The bar in red indicates where IsoPlexis's Net Margin % falls into.

IsoPlexis Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

IsoPlexis's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-105.997	/	16.761
	=	-632.40 %

IsoPlexis's Net Margin for the quarter that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	-33.212	/	3.361
	=	-988.16 %

IsoPlexis (NAS:ISO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

IsoPlexis Net Margin % Related Terms

Thank you for viewing the detailed overview of IsoPlexis's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

IsoPlexis (IsoPlexis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 North East Industrial Road, Branford, CT, USA, 06405

Website

https://www.isoplexis.com

IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.

Executives

Nachum Shamir	director	12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley	officer: Chief Financial Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay	director, officer: Chief Executive Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii	officer: SVP, GC & Secretary	7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath	director	C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm	director	1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia	director	7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers	director	C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley	director	396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho	director, 10 percent owner	C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel	officer: Chief Commercial Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou	officer: Chief Scientific Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar	officer: VP, Finance	35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc	10 percent owner	4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003